Ceramide, a target for antiretroviral therapy
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Studies of ceramide metabolism and function in a wide range of biological processes have revealed a role for this lipid in regulating key cellular responses. Our research on the role of sphingolipids in HIV entry has led to the hypothesis that modulation of ceramide levels in target cells affects their susceptibility to HIV infection by rearranging HIV receptors. Cellular ceramide levels were modulated by application of pharmacological agents such as N -(4-hydroxyphenyl)retinamide (4-HPR, fenretinide), by treatment with sphingomyelinase (Smase), or by exogenous addition of long-chain ceramide, and determined after metabolic incorporation of [ 3 H]sphingosine. Infectivity assays were performed by using a HeLa-derived indicator cell line, TZM-bl, CD4 + lymphocytes, and monocytes. We observed a dose-dependent inhibition by 4-HPR of infection of TZM-bl cells by a broad range of HIV-1 isolates at low micromolar concentrations with an IC 50 of <1 μM for most isolates tested. Nearly complete inhibition was seen at 5 μM, a dose that enhanced ceramide levels by 50-100%, yet was nontoxic to the cells. Treating cells with other pharmacological agents that enhanced ceramide levels, with Smase, or exogenous addition of long-chain ceramide also resulted in inhibition of HIV-1 infection. Enhancing ceramide levels in CD4 + lymphocytes and in monocyte-derived macrophages with 4-HPR or Smase significantly reduced infectivity without toxicity. The minimal toxicity of normal cells exposed to 4-HPR should make the drug exceedingly suitable as an anti-HIV therapeutic.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A RAPID METHOD OF TOTAL LIPID EXTRACTION AND PURIFICATION
Bligh, E. G., & Dyer, W. J. (1959) · Canadian Journal of Biochemistry and Physiology · doi:10.1139/o59-099 · Cited by 54,751
Wei, X., Decker, J. M., Liu, H., Zhang, Z., Arani, R. B., Kilby, J. M., Saag, M. S., Wu, X., Shaw, G. M., & Kappes, J. C. (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.46.6.1896-1905.2002 · Cited by 1,569
A sensitive and specific enzyme-based assay detecting HIV-1 virion fusion in primary T lymphocytes
Cavrois, M., de Noronha, C., & Greene, W. C. (2002) · Nature Biotechnology · doi:10.1038/nbt745 · Cited by 475
Cited by
The emerging field of lipidomics
Wenk, M. R. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1776 · Cited by 1,330
Chan, R., Uchil, P. D., Jin, J., Shui, G., Ott, D. E., Mothes, W., & Wenk, M. R. (2008) · Journal of Virology · doi:10.1128/jvi.00981-08 · Cited by 282
“Interestingly, increasing Cer levels in cells by pharmacological or enzymatic means inhibits HIV infectivity (16), supposedly by inducing CD4 clustering and preventing coreceptor engagement and HIV fusion (15).”
BackgroundRole of Lipids in Virus Replication
Lorizate, M., & Krausslich, H.-G. (2011) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a004820 · Cited by 278
Smith, E. L., & Schuchman, E. H. (2008) · The FASEB Journal · doi:10.1096/fj.08-108043 · Cited by 213
“Intriguingly, incubation of cells with exogenous sphingomyelinase slows the fusion of HIV-1 virus with cells (106).”
BackgroundHIV entry and envelope glycoprotein-mediated fusion
Blumenthal, R., Durell, S., & Viard, M. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.r112.406272 · Cited by 212
“Such inappropriate partners have been identified in the form of overexpressed glycosphingolipids (39), ceramides (40), or other products of the sphingomyelin metabolism (41) and, more recently, dihydrosphingomyelin (42).”
BackgroundSelf-citation
Metadata
- Authors
- Finnegan, C. M., Rawat, S. S., Puri, A., Wang, J. M., Ruscetti, F. W., & Blumenthal, R.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2004-10-15
- Volume
- 101
- Issue
- 43
- Pages
- 15452-15457
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2002633010
- Cited by
- 104
- References
- 3
- FWCI
- 1.86
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.